(IINN) Inspira Technologies Oxy - Ratings and Ratios

Inspira Technologies Oxy B.H.N. Ltd. is a medical device company that specializes in developing innovative life support technologies for treating acute respiratory failure. With a focus on proprietary technologies, the company has developed the INSPIRA ART100, a critical care system used in cardiopulmonary bypass procedures. The companys product is designed for procedures lasting six hours or less, indicating a specific niche within the medical device market.

As a company formerly known as Insense Medical Ltd., Inspira Technologies Oxy B.H.N. Ltd. rebranded in July 2020, signaling a significant shift in its business direction. Incorporated in 2018 and headquartered in Raanana, Israel, the company has been rapidly advancing its product offerings and technologies. With a strong presence in the health care equipment sub-industry, Inspira is poised to capitalize on the growing demand for innovative medical devices.

Analyzing the companys stock performance, we observe a downward trend, with the last price at $0.50, below its SMA20 and SMA50 averages. The ATR indicates a relatively high volatility of 11.05%, suggesting potential for significant price movements. Given the current market capitalization of $13.05M USD and the absence of a P/E ratio, it is clear that the company is not yet profitable. The negative RoE of -212.29 further emphasizes the companys current financial challenges.

Using the available technical and fundamental data, a forecast for IINN can be constructed. The stocks current price is at its 52-week low, and with the SMA200 at $1.00, there is potential for a rebound. However, the lack of profitability and negative RoE indicate significant risks. A potential trading strategy could involve closely monitoring the stocks price movement and waiting for a breakout above the SMA20 or SMA50 averages. If the company can demonstrate significant progress in its product development and commercialization, it may attract investor attention, potentially driving the stock price upwards. A target price could be around $1.00, representing a 100% increase from the current price. However, this is a high-risk trade, and investors should be cautious of the potential for further declines.